U.S. Movers: Agilent, Kimberly-Clark, Maximus, Vanda Pharma

Mukesh Buch
15 Nov, 2013
New York City

Agilent Technologies net tumbled 50% and expects separation in to two companies as early as November 2014. Kimberly-Clark plans to spin-off its $1.6 billion health care business. Maximus net climbed 50% as revenue from health segment jumped 49%.

[R]11:10 AM New York – Agilent Technologies net tumbled 50% and expects separation in to two companies as early as November 2014. Kimberly-Clark plans to spin-off its $1.6 billion health care business. Maximus net climbed 50% as revenue from health segment jumped 49%.[/R]

Agilent Technologies, Inc ((A)) climbed 9.3% or $4.68 to $55.22 after the electronic measurement provider reported revenues in the fourth-quarter ending in September fell 3% to $1.72 billion. Net income in the quarter tumbled 50% to $211 million or 63 cents a diluted share compared to $425 million or $1.20.

Agilent said orders in the quarter jumped 4% to $1.83 billion.

The company added revenue in the fiscal first-quarter between $1.68 billion and $1.70 billion and for the year revenue in the range of $6.95 billion to $7.15 billion.

Agilent said expect completion of separation into two publicly traded companies by early November 2014.

Kimberly-Clark Corporation ((KMB)) gained 84 cents to $110.54 after the sanitary products maker plans to spin-off its health-care business. The tax-free deal would create a stand-alone, publicly traded company with $1.6 billion in annual sales and the transaction is expected to be completed by the end of the third quarter of 2014.

Maximus, Inc ((MMS)) slipped 1.3% or 63 cents to $46.30 after the health and human service provider reported revenues in the fourth-quarter ending in September soared 28% to $384.3 million. Net income in the quarter climbed 50.2% to $35.6 million or 51 cents a diluted share compared to $23.7 million or 34 cents.

Health Services segment revenue for the quarter climbed 49% to $271 million but revenue from the Human Services segment dropped 5% to $113.3 million.

The company expects revenue for the fiscal 2014 in the range between $1.56 billion and $1.65 billion and diluted earnings per share to range between $1.75 and $1.85.

Vanda Pharmaceuticals Inc ((VNDA)) surged 14% to $1.83 to $14.87 after the biopharmaceutical company said it received approvals of HETLIOZ™, for the treatment of non-24-Hour-disorder in the totally blind from U.S. Food and Drug Administration.